Sutro Biopharma’s (STRO) “Overweight” Rating Reaffirmed at Piper Sandler
Sutro Biopharma (NASDAQ:STRO – Get Free Report)‘s stock had its “overweight” rating reissued by equities research analysts at Piper Sandler in a note issued to investors on Friday, Benzinga reports. They currently have a $11.00 target price on the stock. Piper Sandler’s price target would indicate a potential upside of 198.10% from the company’s previous […]
More Stories
StockNews.com Lowers Ally Financial (NYSE:ALLY) to Sell
Ally Financial (NYSE:ALLY – Get Free Report) was downgraded by equities researchers at StockNews.com from a “hold” rating to a...
RLJ Lodging Trust (NYSE:RLJ) Lifted to “Hold” at StockNews.com
RLJ Lodging Trust (NYSE:RLJ – Get Free Report) was upgraded by StockNews.com from a “sell” rating to a “hold” rating...
JetBlue Airways (NASDAQ:JBLU) Upgraded to “Sell” at StockNews.com
JetBlue Airways (NASDAQ:JBLU – Get Free Report) was upgraded by StockNews.com to a “sell” rating in a report issued on...
Prosper Gold (CVE:PGX) Trading Down 4.5% – What’s Next?
Shares of Prosper Gold Corp. (CVE:PGX – Get Free Report) were down 4.5% on Wednesday . The stock traded as...
Christopher J. Hasenberg Inc Sells 30,788 Shares of Invesco QQQ (NASDAQ:QQQ)
Christopher J. Hasenberg Inc lessened its holdings in Invesco QQQ (NASDAQ:QQQ – Free Report) by 51.5% in the 3rd quarter,...
Qtum Achieves Market Cap of $268.82 Million (QTUM)
Qtum (QTUM) traded 6.8% higher against the dollar during the 1 day period ending at 22:00 PM Eastern on October...